25 Lung Cancer Clinical Trials in Phoenix, AZ (2026)

Q: How do I join a clinical trial in Phoenix?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you.

Recruiting Lung Cancer Studies in Phoenix

NCT03851445Recruiting

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to ...

Phoenix, AZPHASE210,000 participantsSWOG Cancer Research Network

View Study Details

NCT05899608Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non...

Phoenix, AZPHASE31,600 participantsSummit Therapeutics

View Study Details

NCT07222566Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults w...

Phoenix, AZPHASE31,410 participantsPfizer

View Study Details

NCT06119581Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated ad...

Phoenix, AZPHASE31,264 participantsEli Lilly and Company

View Study Details

NCT04267848Recruiting

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by...

Phoenix, AZPHASE31,210 participantsNational Cancer Institute (NCI)

View Study Details

NCT06627647Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatmen...

Phoenix, AZPHASE31,160 participantsAstraZeneca

View Study Details

NCT06632327Recruiting

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell ...

Phoenix, AZPHASE31,100 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT05211895Recruiting

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with du...

Phoenix, AZPHASE3860 participantsAstraZeneca

View Study Details

NCT06767514Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival....

Phoenix, AZPHASE3780 participantsSummit Therapeutics

View Study Details

NCT04928846Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...

Phoenix, AZPHASE3768 participantsAbbVie

View Study Details

NCT06890598Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRA...

Phoenix, AZPHASE3700 participantsEli Lilly and Company

View Study Details

NCT06170788Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the co...

Phoenix, AZPHASE3614 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06892548Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecifi...

Phoenix, AZPHASE1594 participantsBioNTech SE

View Study Details

NCT07063745Recruiting

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus p...

Phoenix, AZPHASE2590 participantsBristol-Myers Squibb

View Study Details

NCT05624996Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by ...

Phoenix, AZPHASE3474 participantsNRG Oncology

View Study Details

NCT06686771Recruiting

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study ...

Phoenix, AZPHASE3320 participantsCanadian Cancer Trials Group

View Study Details

NCT04181060Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage II...

Phoenix, AZPHASE3300 participantsNational Cancer Institute (NCI)

View Study Details

NCT06706076Recruiting

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

BH-30643-01 is a Phase 1/2, first-in-human, open label, dose escalation and expansion study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth fac...

Phoenix, AZPHASE1266 participantsBlossomHill Therapeutics

View Study Details

NCT06772623Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to as...

Phoenix, AZPHASE1252 participantsAbbVie

View Study Details

NCT05882058Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard tre...

Phoenix, AZPHASE2204 participantsBoehringer Ingelheim

View Study Details

NCT06996782Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment...

Phoenix, AZPHASE1152 participantsAstraZeneca

View Study Details

NCT04402788Recruiting

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab ...

Phoenix, AZPHASE2138 participantsNational Cancer Institute (NCI)

View Study Details

NCT06362252Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participan...

Phoenix, AZPHASE1123 participantsDaiichi Sankyo

View Study Details

NCT04105270Recruiting

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus ...

Phoenix, AZPHASE282 participantsMasonic Cancer Center, University of Minnesota

View Study Details

NCT05642572Recruiting

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread fr...

Phoenix, AZPHASE266 participantsSWOG Cancer Research Network

View Study Details

About Lung Cancer Clinical Trials in Phoenix

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 25 lung cancer clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 25,027 participants. Research is being sponsored by SWOG Cancer Research Network, Summit Therapeutics, Pfizer and 14 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Phoenix — FAQ

Are there lung cancer clinical trials in Phoenix?

Yes, there are 25 lung cancer clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 25 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 18, 2026 from ClinicalTrials.gov